文献速递神经肌肉病

反义寡核苷酸Tofersen在SOD1-ALS患者中枢神经系统中的分布:尸检组织病例系列

Antisense Oligonucleotide Tofersen Distribution in the Central Nervous System of SOD1-ALS Autopsy Tissue Donors.
PubMed 文献 · JAMA Neurol · 2026-01-01

该横断面尸检组织病例系列纳入8例接受多剂鞘内20-100 mg tofersen的SOD1-ALS患者,分析显示脊髓和运动皮层组织药物浓度与基于个体给药史的预测高度相关,3例近期治疗者腰髓SOD1 mRNA和蛋白降低45%-84%,并观察到脑膜和血管周围淋巴细胞免疫反应。

要点

  • Tofersen在脊髓和运动皮层组织中的浓度与基于给药史的预测高度相关。
  • 近期治疗者腰髓SOD1 mRNA和蛋白降低45%-84%,即使尸检前1-2次计划给药未执行。
  • 5例近期治疗者出现脑膜和血管周围淋巴细胞免疫反应,远期给药者不明显。

核心结论

  • 尸检组织数据首次证实tofersen在人体中枢神经系统的分布符合预测,并在躯体运动系统组织中实现稳健的SOD1蛋白降低。

研究设计与样本

  • 横断面尸检组织病例系列,2018至2026年间在美国3家学术医疗机构进行,纳入8例参与tofersen临床试验或扩展准入项目的SOD1-ALS死亡患者。

主要发现

  • 8例接受tofersen治疗的尸检组织供者(5男3女,年龄范围42-66岁)脊髓和运动皮层组织tofersen浓度与基于个体给药史和临床前药代动力学模型的预测高度相关。
  • 3例近期治疗供者腰髓组织SOD1 mRNA和蛋白降低幅度为45%至84%,尽管尸检前1至2次计划给药未执行。
  • 残存躯体运动神经元显示tofersen转导和低SOD1 mRNA探针杂交信号。
  • 在未接受tofersen的SOD1-ALS对照供者和接受tofersen治疗的供者残存运动神经元中均检测到错误折叠SOD1蛋白包涵体。
  • 5例近期治疗供者观察到脑膜和血管周围淋巴细胞免疫反应,而末次tofersen给药较远的供者未见明显该反应。

关键数值与推荐

  • 参与者接受多剂鞘内20至100 mg tofersen。
  • 3例近期治疗供者腰髓SOD1 mRNA和蛋白降低幅度为45%至84%。

临床怎么用

  • 尸检组织数据支持tofersen鞘内给药后在中枢神经系统运动系统组织中的分布和靶点 engagement,但样本量小,尚不能据此调整临床给药方案。

局限性

  • 为病例系列,样本量仅8例,仅3例用于SOD1降低幅度估计。
  • SOD1降低估计基于与未接受tofersen的SOD1-ALS尸检组织供者队列比较,非同期随机对照。
  • 部分供者尸检前1至2次计划给药未执行,可能影响药物浓度和效应评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Tofersen is a disease-modifying antisense oligonucleotide therapeutic for people living with SOD1-amyotrophic lateral sclerosis (SOD1-ALS). Autopsy tissue donors have provided the first opportunity to study the distribution of intrathecally administered tofersen in human central nervous system tissues. OBJECTIVES: To determine the tissue distribution of tofersen and to provide the first estimates of SOD1 reduction in human somatic motor systems tissues. DESIGN, SETTING, AND PARTICIPANTS: This was a cross-sectional autopsy tissue case series conducted between 2018 and 2026. Autopsies were performed at 3 US academic medical institutions. Tissue samples from 8 deceased patients who lived with SOD1-ALS, participated in tofersen clinical trials (ClinicalTrials.gov Identifiers NCT02623699 [An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 (Tofersen) in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)] and NCT03070119 [Long-Term Evaluation of BIIB067 (Tofersen)]) or the Expanded Access Program, and whose families authorized autopsies were eligible for this study. All autopsy tissue donors known at the time of this study were included (none were excluded). Analyses were conducted between August 2020 and January 2026. EXPOSURES: Participants received multiple intrathecal 20- to 100-mg tofersen doses. MAIN OUTCOMES AND MEASURES: Tofersen tissue concentrations were measured using hybridization enzyme-linked immunosorbent assay (ELISA). SOD1 messenger RNA (mRNA) and protein reduction estimates, defined as percentage SOD1 levels in this study's recently treated autopsy tissue donors compared to a cohort of samples from tofersen-naive SOD1-ALS autopsy tissue donors, were measured using quantitative reverse transcription polymerase chain reaction (PCR) and ELISA. Histological localization of tofersen and SOD1 transcripts were studied using immunohistochemistry and in situ hybridization assays. RESULTS: In 8 tofersen-treated autopsy tissue donors (5 male and 3 female donors; age range, 42-66 years), spinal cord and motor cortical tissue tofersen concentrations strongly correlated with predictions based on individual dosing histories and a preclinical pharmacokinetic model. For 3 recently treated autopsy tissue donors, reductions in lumbar spinal cord tissue SOD1 mRNA and protein levels ranged from 45% to 84% despite not having been administered 1 to 2 scheduled doses before autopsy. Residual somatic motor neurons demonstrated tofersen transduction and low SOD1 mRNA probe hybridization. Misfolded SOD1 protein inclusions were detected in residual motor neurons of tofersen-naive SOD1-ALS tissue donor controls and tofersen-treated tissue donors. Meningeal and perivascular lymphocytic immune responses were observed in 5 recently treated tissue donors but were not apparent in tissue donors with remote final tofersen doses. CONCLUSIONS AND RELEVANCE: This case series presents the first emerging autopsy tissue data confirming the predicted distribution of tofersen and robust SOD1 protein reduction in human somatic motor systems tissues.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Guise AJ, Sellon MT, Roemer SF, et al. Antisense Oligonucleotide Tofersen Distribution in the Central Nervous System of SOD1-ALS Autopsy Tissue Donors. JAMA Neurol. 2026. PMID: 42406382. doi:10.1001/jamaneurol.2026.2195

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。